JAKAFI XR (Ruxolitinib Phosphate) Patent Expiration, LOE Window & CMS Spending

JAKAFI XR (Ruxolitinib Phosphate) by Incyte: FDA Orange Book core substance LOE 2034-05-14 (last listed 2034-07-17), 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIncyte
FDA Application & PathwayN217180 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-05-14
Last Listed Patent or Exclusivity Date2034-07-17
Orange Book Patents (*PED Extensions)265 patents (60 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.